Inato
Matching research sites to the right clinical trial protocols, unlocking site potential worldwide.
Matching research sites to the right clinical trial protocols, unlocking site potential worldwide.
Published Oct 6, 2026
No public metrics were available for maximum record throughput, concurrency, or enterprise SLA commitments.
Public documentation detailing APIs, supported EHR integrations, and standards (HL7/FHIR) was not available in the materials reviewed.
2. Two-sided network design intended to support sponsor–site interactions and structured Enrollment Plans that can be reviewed and validated before sponsor selection.
Vendor-facing pages emphasize ease of trial review compared with reviewing full protocols, reduced feasibility burden, and sponsor feedback timelines. Vendor materials also present pre-screening features that the vendor claims reduce chart review time and support de-identification/redaction workflows.
Vendor materials list survey-like statistics indicating increased selection likelihood and reduced burden based on internal surveys. These appear to be internal survey results with undisclosed methodology and sampling; they are useful as directional signals but are not equivalent to independent benchmarks.
Get a comprehensive analysis of Inato including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Balanced caveat: Several of these value propositions are based on vendor statements and internal metrics; independent validation was limited in the materials reviewed.
Interpretation: Inato has limited visible coverage on mainstream B2B review platforms based on the sources reviewed, or reviews may be gated/hard to access. This should be considered for procurement processes that rely on third-party review validation.
Reddit posts and comments provide informal, anecdotal feedback from site staff and community members. These comments are not statistically representative but can highlight areas of friction.
Representative neutral/positive mentions:
Representative critical mentions / limitations:
Because independent third-party review data is limited in the dataset reviewed, churn reasons are inferred from community feedback and typical category dynamics:
Vendor materials reference a case study describing outcomes such as reductions in patient chart review time from hours to minutes.
Critical evaluation:
Buyers should request from the vendor:
Inato is a clinical trials marketplace and platform designed to connect trial sponsors and CROs with research sites, with particular focus on community-based sites. The platform includes tooling that uses machine learning to support feasibility and patient identification/pre-screening. Inato presents the product as a single platform that spans early planning, site selection, and enrollment, with emphasis on improving access and inclusion in clinical research.
From the sponsor perspective, the platform is intended to support protocol planning and site selection by using site and patient-access data and by structuring site applications (Enrollment Plans) that Inato verifies before making recommendations. From the site perspective, the marketplace and pre-screening features are provided at no charge to sites.
Vendor-published metrics indicate a multi-country footprint and participation by multiple sponsors and research sites; these figures were published by the vendor and were not independently audited in the materials reviewed.